The European Schizophrenia Cohort EuroSC EuroSC The European Schizophrenia Cohort PEF73208 Portail Épidémiologie-France Portail Épidémiologie-France | Health Databases Portail Épidémiologie-France 2026 12/04/2026 https://epidemiologie-france.aviesan.fr/ Portail Épidémiologie-France Portail Epidemiologie-France Jean-Michel Azorin 26/08/2015 05/07/2016 05/09/2017 4 2 Jean-Michel Azorin EuroSC - The European Schizophrenia Cohort EuroSC - The European Schizophrenia Cohort The European Schizophrenia Cohort EuroSC EuroSC The European Schizophrenia Cohort Azorin Jean Michel Paul Bebbington EuroSC Research Group (Allemagne, Angleterre, France) EuroSC Research Group (Germany, England, France) Royal Free and University College Medical School.. Pour la partie Francaise : Hôpital Sainte Marguerite , Marseille - AP-HM Southern Regional Hospitals - - Royal Free and University College Medical School, UCL - Wolfson Building 48 Riding House Street London W1W 7EY, UK Lundbeck A/S ; German Federal Ministry of Education and Research Lundbeck A/S ; German Federal Ministry of Education and Research AP-HM Southern Regional Hospitals Royal Free and University College Medical School, UCL Azorin Jean Michel Paul Bebbington Jean-Michel Azorin 26/08/2015 05/07/2016 05/09/2017 05/07/2016 4 2 Jean-Michel Azorin CNIL CNIL CNIL Schizophrénie prise en charge traitement qualité de vie soins coût schizophrenia management treatment quality of life care cost Psychologie et psychiatrie Psychology and psychiatry Produits de santé Systèmes de soins et accès aux soins Medicine Healthcare system and access to health care services Objectif de la base de données : L'objectif primaire de EuroSC est de rapporter les différents types de traitement et de soins ainsi que les résultats cliniques. Les objectifs secondaires comprennent :l'évaluation des besoins de traitement par rapport aux résultats, le calcul de la consommation des ressources associé à différentes méthodes de soins, et l'identification des facteurs pronostiques Database objective : The main aim of EuroSC is to report on the different types of treatment and care, as well as clinical outcome. Secondary aims include: assessment of treatment requirements in relation to outcome, calculation of resource usage with regards to different care methods and identification of prognostic factors. 1998 2002 Collecte des données terminée Data collection completed France Europe - France (Lille, Lyon, Marseille, Clermont-Ferrand, Toulon) Europe — France (Lille, Lyon, Marseilles, Clermont-Ferrand, Toulon) International individuel individuals Patients âgés de 18 à 64 ans au moment de l'inclusion Diagnostic de schizophrénie établi Consentement du participant Patients between 18 and 64 years old at baseline; Established schizophrenia diagnosis; Participant consent Nombre d'individus : France :288 UK : 302 ; Germany : 618 Number of individuals: France: 288; UK: 302; Germany: 618 Recrutement via une sélection de services ou établissements de santé Recruiting through a selection of health institutions and services Adulte (19 à 24 ans) Adulte (25 à 44 ans) Adulte (45 à 64 ans) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Sujets malades Sick population F20 - Schizophrénie F20 - Schizophrenia Masculin Féminin Male Female Bases de données issues d’enquêtes Study databases Etudes de cohortes Cohort study Données cliniques : Antécédents psychiatriques, informations socio-démographiques, diagnostic, traitement, état spychatrique (SCAN SCAN, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI), The Global Assessment of Functioning (GAF), Global Assessment of Relational Functioning (GARF)) et social, consommation de médicaments et effets secondaires, observance du traitement (The Rating of Medication Influences (ROMI) Scale,), voie par le biais du système de soins et de la consommation de ressources de services Données déclaratives : Face à face Clinical data: Psychiatric history, sociodemographic information, diagnosis, treatment, psychiatric and social state (SCAN SCAN, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), Global Assessment of Relational Functioning (GARF)) medication use and side effects, treatment adherence (Rating of Medication Influences (ROMI) Scale,), healthcare system pathway and usage of service resources. Declarative data: Face to face interview Evénements de santé/morbidité Consommation de soins/services de santé Qualité de vie/santé perçue Health event/morbidity Health care consumption and services Quality of life/health perception Hospitalisation Consultations (médicales/paramédicales) Produits de santé Hospitalization Medical/paramedical consultation Medicines consumption Longitudinal: Cohort/Event-based Azorin Jean Michel Paul Bebbington Tous les 6 mois pendant 2 ans suite à l'inclusion Every 6 months for 2 years following enrolment. Par le personnel médical des centres concernés By medical staff in the centres concerned. Dossier clinique : Antécédents psychiatriques, informations socio-démographiques, diagnostic, traitement, état spychatrique (SCAN SCAN, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI), The Global Assessment of Functioning (GAF), Global Assessment of Relational Functioning (GARF)) et social, consommation de médicaments et effets secondaires, observance du traitement (The Rating of Medication Influences (ROMI) Scale,), voie par le biais du système de soins et de la consommation de ressources de services Direct physical measures: Psychiatric history, sociodemographic information, diagnosis, treatment, psychiatric and social state (SCAN SCAN, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), Global Assessment of Relational Functioning (GARF)) medication use and side effects, treatment adherence (Rating of Medication Influences (ROMI) Scale,), healthcare system pathway and usage of service resources. Face à face : Qualité de vie (Medical Outcome Study Short Form 36 (SF36), The Social and Occupational Functioning Assessment Scale (SOFAS), Quality of Life Interview (QoLI), EuroQoL) Face to face interview: Qualité de vie (Medical Outcome Study Short Form 36 (SF36), The Social and Occupational Functioning Assessment Scale (SOFAS), Quality of Life Interview (QoLI), EuroQoL) Contacter le responsable scientifique Contact the scientist in charge. Contacter le responsable scientifique Contact the scientist in charge. Contacter le responsable scientifique Contact the scientist in charge. http://www.biomedcentral.com/1472-6963/12/269#B4 http://tinyurl.com/PUBMED-EUROSC http://www.biomedcentral.com/1472-6963/12/269#B4 http://tinyurl.com/PUBMED-EUROSC